Skip to content
TriangleGet started
← Mantle Cell Lymphoma

FOR PATIENTS · SOURCE READING

Treatment of Recurrent Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Mantle-cell-specific source passages within broader non-Hodgkin lymphoma sections Only selected blocks explicitly name mantle cell lymphoma. Full owning sections include other lymphomas and must not be relabeled mantle-cell-only.

Context from the original source

Treatment of aggressive, recurrent non-Hodgkin lymphoma may include the following:

Source links and citations

For mantle cell lymphoma, treatment may include the following:

Source links and citations

For mantle cell lymphoma, treatment may include the following:

Bruton tyrosine kinase inhibitor therapy.

Source links and citations

For mantle cell lymphoma, treatment may include the following:

Rituximab with or without a tyrosine kinase inhibitor (ibrutinib).

Source links and citations

For mantle cell lymphoma, treatment may include the following:

Lenalidomide.

Source links and citations

For mantle cell lymphoma, treatment may include the following:

A clinical trial of lenalidomide with monoclonal antibody therapy.

For mantle cell lymphoma, treatment may include the following:

A clinical trial comparing lenalidomide to other therapy.

For mantle cell lymphoma, treatment may include the following:

A clinical trial of proteasome inhibitor therapy (bortezomib).

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice